- Home
- VTGN vs PASG Comparison
VTGN vs PASG Comparison
Compare VTGN & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | PASG |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 26.0M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VTGN | PASG |
|---|---|---|
| Price | $0.56 | $9.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $0.90 | ★ $24.80 |
| AVG Volume (30 Days) | ★ 422.3K | 30.0K |
| Earning Date | 02-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.28 |
| 52 Week High | $5.14 | $20.00 |
Technical Indicators
Market Signals| Indicator | VTGN | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 58.49 |
| Support Level | $0.50 | $8.02 |
| Resistance Level | $0.66 | $10.15 |
| Average True Range (ATR) | 0.04 | 1.07 |
| MACD | -0.00 | 0.46 |
| Stochastic Oscillator | 34.57 | 72.26 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.